NCT04128423: Study of AMV564 in Subjects With Advanced Solid Tumors

NCT04128423
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior treatment of CAR T-cell therapy or T-cell engager therapy; Patients with known CNS disease involvement
https://ClinicalTrials.gov/show/NCT04128423

Comments are closed.

Up ↑